Drug-Drug Interaction Clinical Trial
Official title:
An Open-label Study to Assess the Potential for Pre-systemic Inhibition of Cytochrome P450 3A4 (CYP3A) by Idebenone in Healthy Male Subjects Using Midazolam as a Substrate
Verified date | October 2017 |
Source | Santhera Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I open label study is conducted to assess the potential pharmacokinetic interaction of Raxone® with midazolam in healthy male volunteers
Status | Completed |
Enrollment | 32 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male aged 18 to 55 years. 2. A Body Mass Index (BMI) of 18-30. BMI = Body weight (kg) / Height (m)2. 3. Male subject willing to use an acceptable effective contraceptive measure for the entire duration of study participation. 4. No clinically significant abnormal serum biochemistry, haematology and urine examination values. 5. A negative urinary test for drugs of abuse and alcohol breath screen. A positive alcohol test may be repeated at the discretion of the Investigator. 6. Negative HIV and Hepatitis B and C results. 7. No clinically significant abnormalities in 12 lead electrocardiogram (ECG). 8. No clinically significant abnormalities in blood pressure, pulse or oral temperature. 9. No allergy or sensitivity to midazolam, idebenone or any of their excipients. 10. No current or past medical condition that might significantly affect the pharmacokinetic or pharmacodynamic response to midazolam. 11. Subject must be available to complete the study (including follow-up visit). 12. Subject must satisfy a medical examiner about their fitness to participate in the study. 13. Subject must provide written informed consent to participate in the study. 14. Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research. Exclusion Criteria: 1. A clinically significant history of gastrointestinal disorder likely to influence drug absorption. 2. Use of any medication (prescription or OTC, including health supplements and herbal remedies, except paracetamol, within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of trial medication. 3. Use of any medication known to induce or inhibit any of the enzymes within the CYP3A system within 28 days of Day 1, or grapefruit within 7 days of Day 1 4. Evidence of renal, hepatic dysfunction, cardiovascular or metabolic dysfunction. 5. History of obstructive sleep apnoea syndrome. 6. History of any significant drug allergy including benzodiazepine. 7. A clinically significant history of drug or alcohol abuse. 8. Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function). 9. Participation in a clinical trial of a New Chemical Entity within the previous 3 months or of a Marketed Product within the previous 30 days (or 5 times the half-life, whichever is longer). 10. Donation of 450 mL or more blood within the previous 3 months. 11. Smoking or use of tobacco products or substitutes within the previous 6 months, as determined at the Screening visit. 12. Need for administrative or legal supervision. 13. Subject who would receive more than 4500 euros as indemnities for participation in biomedical research within 12 months, including the indemnities for the present study. |
Country | Name | City | State |
---|---|---|---|
France | Eurofins Optimed | Gières |
Lead Sponsor | Collaborator |
---|---|
Santhera Pharmaceuticals |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Curve (AUC) from the time of dosing to the time of the last observed concentration (AUC0-t) | 13 days | ||
Primary | Area Under the Curve (AUC) extrapolated to infinity from dosing time, based on the last observed concentration (AUC0-8) | 13 days | ||
Primary | Maximum plasma concentration (Cmax) | 13 days | ||
Primary | Time to Maximum plasma concentration (Cmax) during a dosing interval (tmax) | 13 days | ||
Primary | Terminal elimination half-life (t1/2) | 13 days | ||
Primary | Clearance, calculated as dose/AUC0-8 (CL/F) | 13 days | ||
Primary | Volume of distribution during terminal phase after non-intravenous administration (Vz/F) | 13 days | ||
Secondary | Area Under the Curve (AUC) from the time of dosing to the time of the last observed concentration (AUC0-t) | 13 days | ||
Secondary | Area Under the Curve (AUC) extrapolated to infinity from dosing time, based on the last observed concentration (AUC0-8) | 13 days | ||
Secondary | Maximum plasma concentration (Cmax) | 13 days | ||
Secondary | Time to Maximum plasma concentration (Cmax) during a dosing interval (tmax) | 13 days | ||
Secondary | Terminal elimination half-life (t1/2) | 13 days | ||
Secondary | Clearance (CL) | 13 days | ||
Secondary | Clearance, calculated as dose/AUC0-8 (CL/F) | 13 days | ||
Secondary | Volume of distribution (Vz) | 13 days | ||
Secondary | Volume of distribution during terminal phase after non-intravenous administration (Vz/F) | 13 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05692570 -
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04328766 -
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03990129 -
Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03985969 -
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
|
Phase 1 | |
Completed |
NCT03302845 -
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01361217 -
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
|
N/A | |
Completed |
NCT06066060 -
A DDI Study of JMKX000623 and Metformin Hydrochloride
|
Phase 1 | |
Completed |
NCT03723395 -
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
|
Phase 1 | |
Recruiting |
NCT05789173 -
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
|
Early Phase 1 | |
Completed |
NCT04598542 -
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05044962 -
Kuwa Free! - Live Free!
|
N/A | |
Completed |
NCT04487145 -
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
|
Phase 4 | |
Completed |
NCT05108051 -
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
|
Phase 1 | |
Active, not recruiting |
NCT04669678 -
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
|
Phase 4 | |
Completed |
NCT01991327 -
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
|
Phase 1 | |
Completed |
NCT04218513 -
Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
|
Phase 1 | |
Completed |
NCT05492318 -
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
|
Phase 1 | |
Completed |
NCT01309854 -
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05339672 -
Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
|
||
Completed |
NCT05306379 -
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
|
Phase 1 |